zerona Z6, Руководство пользователя

Страница: 15 / 44

GENERAL INFORMATION | 10
BENEFITS
In the past, Erchonia’s low level laser technology was only available in a doctor’s office for
circumference reduction of the waist, hips and thighs. Erchonia first received FDA market
clearance in 2010 as a prescription only device.
The application of Erchonia’s low level laser technology has been proven through clinical trials to
induce transitory pore formation, releasing collected fatty material, which is absorbed, degraded
by the lymphatic system and removed from the treated area, creating a slimming outcome based
upon the volume reduction of fat cells.
In 2008, Erchonia conducted a yearlong clinical trial study to determine the effectiveness of the
Erchonia Zerona for non-invasive circumference reduction of the waist, hips and thighs with 6
treatments over a 2-week time frame.
A double-blind, randomized, multi-site, and placebo-controlled study with 67 participants was
conducted in which patients on average, lost 3.50 inches/ 8.9 cm* from their waist, hips and
thighs. These results are dramatic compared to the placebo group, which only lost an average of
half an inch.
In 2014, 22 participants between the ages of 18 to 65 participated in a multi-site clinical study that
was conducted in the United States using the Zerona Z6 OTC device. Participants received six
treatments over a two-week period. Throughout the study, participants were measured at the end
of each week. The participants saw a combined circumference reduction of the waist, hips and
thighs averaging 3.7 inches at the end of 2 weeks.
To achieve the best results, you must carefully read and follow the instructions in this booklet.
*individual results may vary